Circulating Tumor Cells Market by Product, Technology, Application, and Specimen – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2029
Overview
Circulating Tumor Cells Market size was valued at US$ 11.59 Bn. in 2022 and the total revenue is expected to grow at 11.7% through 2023 to 2029, reaching nearly US$ 25.15 Bn.
Circulating Tumor Cells Market Overview:
Circulating tumor cells (CTCs) have recently been discovered to be useful biomarkers for diagnostic and prognostic purposes, as well as for monitoring therapeutic responses to therapies. CTCs are rare cells that can be found in a milliliter of peripheral blood as a single CTC surrounded by 1 million white blood cells and 1 billion red blood cells.
To know about the Research Methodology :- Request Free Sample Report
Circulating Tumor Cells Market Dynamics:
Circulating tumor cells are regarded as a promising method in cancer diagnostics due to their non-invasiveness and benefits. Furthermore, developments in chip technology are another important driver driving the market. Extensive translational and clinical cancer research projects in the field of circulating tumor cells (CTCs) have been done over the last several decades. Several government organizations, such as the American Association of Cancer Research and the American Society of Clinical Oncology, are researching circulating tumor cells technology to use circulating tumor cells as a surrogate marker for determining cancer progression is anticipated to boost the growth of the market.
Several tumor markers that have recently been introduced can be used in conjunction with companion diagnostics to monitor or diagnose a wide range of malignancies. One of the few reasons driving demand in this market is the widespread use of companion diagnostics in assessing tumor eradication features of cytotoxic medications. The development of CTC-based assays, which can aid in cancer diagnosis, is a continuing effort among key stakeholders.
Concerns about the biomarker's reproducibility and consistency of isolation, as well as the association between quantification and cancer prognosis, are limiting factors limiting the biomarker's clinical value. Although numerous benchtop tools for analyzing and distinguishing circulating tumor cells from other blood cells are widely available, it is challenging to define these cells due to their diverse morphologies.
Circulating Tumor Cells Market Segment Analysis:
The CTC detection segment is anticipated to adhere to the growth of the Circulating Tumor Cells Market.
The CTC detection and enrichment methods segment, which accounted for 65.8% of sales in 2022, was the most profitable. Over the projection period, the availability of various technologies for enriching circulating tumor cells in cancer detection is projected to have a major impact on segment growth. Furthermore, the market expansion is likely to be fueled by positive or negative enrichment of circulating tumor cells based on biological features.
An effective enrichment method improves sensitivity, selectivity, and yield, ensuring that this field's clinical translation is successful. Magnetic beads-based enrichment, centrifugal force, filtration, and other physical features such as size, density, deformity, and electric charges are among the several detecting procedures.
Advancements in technologies like immunofluorescence, next-generation sequencing, FISH, and qPCR are expected to increase the clinical value of these cells, resulting in faster revenue growth for CTC analyses. Several firms are investing in the development of CTC analysis and downstream assay items. Vortex Biosciences, for example, offers immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics as CTC analysis services.
The research segment is estimated to grab larger market attention in the Circulating Tumor Cells Market.
In 2022, the research segment led the market, accounting for 72.8 % of revenue. Cancer metastasis is thought to be aided by circulating tumor cells. Enumeration of circulating tumor cells is still mostly a research technique. The attention has recently switched to the characterization and isolation of circulating tumor cells, which can provide considerable prospects in predictive testing research.
As a result of the considerable advancements in cancer research, items on the market are primarily designed for use in research settings. Parsortix Technology, Target Selector Platform, and Apostema, DEPArray System, VTX-1, Adna Test Technology are some of the important products that have contributed to a substantial proportion of research settings.
The devices or systems segment is supplementing the growth of the Circulating Tumor Cells Market.
In 2022, the devices or systems category led the market, accounting for 42.8 % of total revenue. This is due to the large range of products available in this area, as well as impending advancements in microfluidics technology. The adoption of manufactured glass microchips to overcome obstacles and improve technical completeness for mass production is projected to move this market forward. Blood collection tubes' revenue growth is being hampered by the development of automated tools that eliminate the need for more blood collection tubes. When reagent-equipped tubes are utilized, the transportation is free of additional laboratory consumables and transfer tubes, resulting in cost savings.
Kits and reagents, on the other hand, have contributed significantly to income due to their frequent purchase and high utilization rates. A group of researchers investigated cancer cell lines employing kits available in the marketplace due to their convenience of use and the consequent product of label-free live cells that can then be employed in downstream analyses.
Regional Insights:
North America is dominating the growth of the regional market in the forecast period.
North America dominated the Circulating Tumor Cells (CTCs) market in 2022, accounting for 51.2 % of total revenue. Key players in the region include Advanced Cell Diagnostics, Apocell, Inc., Aviva Biosciences, Biocept, Inc., Biofluidica, Inc., and CellTraffix, Inc. Due to the obvious significant proportion of the U.S. market, these companies are pursuing a variety of measures to strengthen their market position. For example, Biocept, Inc. launched the Target Selector pan-TRK assay to detect TRK proteins in November 2021. This test uses the company's circulating tumor cells technology to detect TRK gene changes in blood samples. As a result of these challenges, the country now has more cost-effective, noninvasive biomarker testing for cancer screening.
Furthermore, the existence of a large population of cancer susceptibility increased market penetration rates, and technologically advanced cancer care infrastructure are some of the important factors contributing to its huge share. The Asia Pacific, on the other hand, is expected to develop at a fast pace due to high unmet diagnostic needs and expanding rapidly patient awareness of cancer early detection and risk assessment.
The objective of the report is to present a comprehensive analysis of the Circulating Tumor Cells Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Circulating Tumor Cells Market dynamics, structure by analyzing the market segments and projecting the Circulating Tumor Cells Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Circulating Tumor Cells Market make the report investor’s guide.
Circulating Tumor Cells Market Scope: Inquire before buying
| Circulating Tumor Cells Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 11.59 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 11.7% | Market Size in 2029: | US $ 25.15 Bn. |
| Segments Covered: | by Product | Clinical Risk Assessment Screening and Monitoring Research Cancer Stem Cell & Tumorogenesis Research Drug/Therapy Development |
|
| by Technology | CTC Detection & Enrichment Methods CTC Direct Detection Methods CTC Analysis |
||
| by Application | Kits & Reagents Blood Collection Tubes Devices or Systems |
||
| by Specimen | Blood Bone Marrow Other Body Fluids |
||
Circulating Tumor Cells Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (razil, Argentina Rest of South America)
Circulating Tumor Cells Market Key Players:
1. QIAGEN
2. Bio-Techne Corporation
3. Precision for Medicine
4. AVIVA Biosciences
5. BIOCEPT, Inc.
6. Bio CEP Ltd.
7. Fluxion Biosciences, Inc.
8. Greiner Bio One International GmbH
9. Ikonisys Inc.
10. Miltenyi Biotec
11. IVDiagnostics
12. BioFluidica
13. Canopus Bioscience Ltd.
14. Biolidics Limited
15. Creativ MicroTech, Inc.
16. LungLife AI, Inc.
17. Epic Sciences
18. Rarecells Diagnostics
19. ScreenCell
20. Menarini Silicon Biosystems
21. LineaRx, Inc. (Vitatex, Inc.)
22. Sysmex Corporation
23. STEMCELL Technologies, Inc.
FAQs:
1. What is the Circulating Tumor Cells market value in 2022?
Ans: The Circulating Tumor Cells market value in 2022 was estimated as 11.59 Billion USD.
2. Which Technology Type is likely to dominate the Circulating Tumor Cells market growth?
Ans: CTC detection & enrichment methods dominated the CTCs market. This is attributable to the availability of different methods for the enrichment of circulating tumor cells in cancer detection.
3. Which Region is expected to dominate the Circulating Tumor Cells market during the forecast period?
Ans: In 2022, North America dominated the Circulating Tumor Cells (CTCs) market and accounted for the largest revenue share of 51.2%.
4. What are the factors driving the Circulating Tumor Cells market?
Ans: Key factors that are driving the CTCs market growth include rising cancer prevalence, increasing preference for non-invasive cancer diagnosis, and technological advancements in CTC isolation and analysis.
5. Who are the key players in the Circulating Tumor Cells market?
Ans: Some key players operating in the CTCs market include Greiner Bio-One International GmbH; QIAGEN; Bio-Techne Corporation; Menarini Silicon Biosystems; Sysmex Corporation; and Biocept, Inc.